Terms: = Leukemia AND SYK, P43405, 6850, ENSG00000165025
344 results:
1. [Research Progress of Targeted Therapy for Chronic Lymphocytic leukemia/Small Lymphocytic Lymphoma --Review].
Chen D; Wang MY; Tian C
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):643-646. PubMed ID: 38660880
[TBL] [Abstract] [Full Text] [Related]
2. FLI1 induces erythroleukemia through opposing effects on UBASH3A and UBASH3B expression.
Wang J; Wang C; Hu A; Yu K; Kuang Y; Gajendran B; Zacksenhaus E; Sample KM; Xiao X; Liu W; Ben-David Y
BMC Cancer; 2024 Mar; 24(1):326. PubMed ID: 38461240
[TBL] [Abstract] [Full Text] [Related]
3. Aminopeptidase N/CD13 Crosslinking Promotes the Activation and Membrane Expression of Integrin CD11b/CD18.
Díaz-Alvarez L; Martínez-Sánchez ME; Gray E; Pérez-Figueroa E; Ortega E
Biomolecules; 2023 Oct; 13(10):. PubMed ID: 37892170
[TBL] [Abstract] [Full Text] [Related]
4. A Non-Canonical Role for the Glycosyltransferase Enzyme UGT2B17 as a Novel Constituent of the B Cell Receptor Signalosome.
Wagner A; Rouleau M; Villeneuve L; Le T; Peltier C; Allain ÉP; Beaudoin C; Tremblay S; Courtier F; Nguyen Van Long F; Laverdière I; Lévesque É; Banerji V; Vanura K; Guillemette C
Cells; 2023 May; 12(9):. PubMed ID: 37174695
[TBL] [Abstract] [Full Text] [Related]
5. Targeting and Monitoring Acute Myeloid Leukaemia with Nucleophosmin-1 (
Chin L; Wong CYG; Gill H
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834572
[TBL] [Abstract] [Full Text] [Related]
6. ArtinM Cytotoxicity in B Cells Derived from Non-Hodgkin's Lymphoma Depends on syk and Src Family Kinases.
Barboza BR; Thomaz SMO; Junior AC; Espreafico EM; Miyamoto JG; Tashima AK; Camacho MF; Zelanis A; Roque-Barreira MC; da Silva TA
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674590
[TBL] [Abstract] [Full Text] [Related]
7. Heterogeneity of Patient-Derived Acute Myeloid leukemia Cells Subjected to syk In Vitro Inhibition.
Brattås MK; Hemsing AL; Rye KP; Hatfield KJ; Reikvam H
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499034
[TBL] [Abstract] [Full Text] [Related]
8. Recent advances in understanding spleen tyrosine kinase (syk) in human biology and disease, with a focus on fostamatinib.
Cooper N; Ghanima W; Hill QA; Nicolson PL; Markovtsov V; Kessler C
Platelets; 2023 Dec; 34(1):2131751. PubMed ID: 36331249
[TBL] [Abstract] [Full Text] [Related]
9. Population Pharmacokinetics of Mivavotinib (TAK-659), a Dual Spleen Tyrosine Kinase and FMS-Like Tyrosine Kinase 3 Inhibitor, in Patients With Advanced Solid Tumors or Hematologic Malignancies.
Li C; Watson K; Wang S; Diderichsen PM; Gupta N
J Clin Pharmacol; 2023 Mar; 63(3):326-337. PubMed ID: 36309821
[TBL] [Abstract] [Full Text] [Related]
10. Novel peanut-specific human IgE monoclonal antibodies enable screens for inhibitors of the effector phase in food allergy.
Suber J; Zhang Y; Ye P; Guo R; Burks AW; Kulis MD; Smith SA; Iweala OI
Front Immunol; 2022; 13():974374. PubMed ID: 36248809
[TBL] [Abstract] [Full Text] [Related]
11. Targeting lipid-protein interaction to treat syk-mediated acute myeloid leukemia.
Singaram I; Sharma A; Pant S; Lihan M; Park MJ; Pergande M; Buwaneka P; Hu Y; Mahmud N; Kim YM; Cologna S; Gevorgyan V; Khan I; Tajkhorshid E; Cho W
Nat Chem Biol; 2023 Feb; 19(2):239-250. PubMed ID: 36229686
[TBL] [Abstract] [Full Text] [Related]
12. A phase Ib trial of mivavotinib (TAK-659), a dual syk/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia.
Pratz KW; Kaplan J; Levy M; Bixby D; Burke PW; Erba H; Wise-Draper TM; Roboz GJ; Papadantonakis N; Rajkhowa T; Hernandez D; Dobler I; Gregory RC; Li C; Wang S; Stumpo K; Kannan K; Miao H; Levis M
Haematologica; 2023 Mar; 108(3):705-716. PubMed ID: 36226495
[TBL] [Abstract] [Full Text] [Related]
13. CD93 promotes acute myeloid leukemia development and is a potential therapeutic target.
Jia J; Liu B; Wang D; Wang X; Song L; Ren Y; Guo Z; Ma K; Cui C
Exp Cell Res; 2022 Nov; 420(2):113361. PubMed ID: 36152731
[TBL] [Abstract] [Full Text] [Related]
14. Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid leukemia through Suppression of Stemness.
Liu ACH; Cathelin S; Yang Y; Dai DL; Ayyathan DM; Hosseini M; Minden MD; Tierens A; Chan SM
Cancer Res; 2022 Dec; 82(23):4325-4339. PubMed ID: 36150062
[TBL] [Abstract] [Full Text] [Related]
15. BTK-independent regulation of calcium signalling downstream of the B-cell receptor in malignant B-cells.
Arthur R; Wathen A; Lemm EA; Stevenson FK; Forconi F; Linley AJ; Steele AJ; Packham G; Valle-Argos B
Cell Signal; 2022 Aug; 96():110358. PubMed ID: 35597428
[TBL] [Abstract] [Full Text] [Related]
16. Modeling the B-cell receptor signaling on single cell level reveals a stable network circuit topology between nonmalignant B cells and chronic lymphocytic leukemia cells and between untreated cells and cells treated with kinase inhibitors.
Wolf C; Maus C; Persicke MRO; Filarsky K; Tausch E; Schneider C; Döhner H; Stilgenbauer S; Lichter P; Höfer T; Mertens D
Int J Cancer; 2022 Sep; 151(5):783-796. PubMed ID: 35527719
[TBL] [Abstract] [Full Text] [Related]
17. syk and ZAP70 kinases in autoimmunity and lymphoid malignancies.
Leveille E; Chan LN; Mirza AS; Kume K; Müschen M
Cell Signal; 2022 Jun; 94():110331. PubMed ID: 35398488
[TBL] [Abstract] [Full Text] [Related]
18. Emerging Targeted Therapy for Specific Genomic Abnormalities in Acute Myeloid leukemia.
Chi SG; Minami Y
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216478
[TBL] [Abstract] [Full Text] [Related]
19. Evolution of TP53 abnormalities during CLL disease course is associated with telomere length changes.
Olbertova H; Plevova K; Pavlova S; Malcikova J; Kotaskova J; Stranska K; Spunarova M; Trbusek M; Navrkalova V; Dvorackova B; Tom N; Pal K; Jarosova M; Brychtova Y; Panovska A; Doubek M; Pospisilova S
BMC Cancer; 2022 Feb; 22(1):137. PubMed ID: 35114947
[TBL] [Abstract] [Full Text] [Related]
20. Kinase Inhibition as Treatment for Acute and Chronic Graft-
Braun LM; Zeiser R
Front Immunol; 2021; 12():760199. PubMed ID: 34868001
[TBL] [Abstract] [Full Text] [Related]
[Next]
